SCHEMBL1189647

SCHEMBL1189647

CSc1cccc(NC(=O)Nc2ccc3c(c2)CCN(C(=O)OC(C)(C)C)C3)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.55
▸ NPC1 O15118 5/20 0.52
▸ RAB9A P51151 5/20 0.52
▸ NR1H2 P55055 1/20 0.49
▸ KMT2A Q03164 4/20 0.48
▸ MAPT P10636 3/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ PIK3CA P42336 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1188616 0.91 ESR2 (0.58) ESR2NPC1RAB9ANR1H2KMT2A
SCHEMBL1188540 0.88 ESR2 (0.62) ESR2NPC1RAB9ANR1H2KMT2A
SCHEMBL1188304 0.87 ESR2 (0.58) ESR2NPC1RAB9ANR1H2MAPK1
SCHEMBL1189027 0.86 ESR2 (0.57) ESR2NPC1RAB9ANR1H2KMT2A
SCHEMBL1188717 0.86 ESR2 (0.57) ESR2NPC1RAB9ANR1H2MAPT
SCHEMBL1188325 0.85 NPC1 (0.61) ESR2NPC1RAB9ANR1H2MAPT
SCHEMBL1187262 0.84 ESR2 (0.55) ESR2NPC1RAB9ANR1H2PIK3CA
SCHEMBL1188136 0.84 ESR2 (0.55) ESR2NPC1RAB9ANR1H2KMT2A
SCHEMBL1187894 0.84 ESR2 (0.55) ESR2NPC1RAB9ANR1H2KMT2A
SCHEMBL1187044 0.84 ESR2 (0.55) ESR2NPC1RAB9ANR1H2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 — — US disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 — — EP disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 — — US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT ESR2 3292/4885NPC1 269/4885RAB9A 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback